• FDA-Grants-Regular-Approval-to-Rubraca-for-Metastatic-Castration-Resistant-Prostate-Cancer

    Originally published by our sister publication Clinical Oncology NewsBy Clinical Oncology News StaffThe FDA approved rucaparib (Rubraca, pharmaand GmbH) for adults with a deleterious BRCA mutation (BRCAm) (germline and/or somatic)–associated metastatic castration-resistant prostate cancer (mCRPC) previously treated with an androgen receptor–directed therapy. Patients should be selected for therapy using an FDA-approved companion diagnostic. Rucaparib was granted accelerated approval
  • FDA-Approves-Rybrevant-Faspro-for-Subcutaneous-Injection

    Originally published by our sister publication Clinical Oncology NewsBy Clinical Oncology News StaffThe FDA approved amivantamab and hyaluronidase-lpuj (Rybrevant Faspro, Janssen Biotech) for subcutaneous injection for adult patients across all indications approved for the IV formulation of amivantamab (Rybrevant, Janssen). See the prescribing information for the specific indications.The subcutaneous injection of amivantamab and hyaluronidase-lpuj was evaluated in PALOMA-3, a randomized, open-la

Follow @newsl_pharmacy on Twitter!